The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Should we adapt treatment based on MRD status in MM?
Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK, discusses the question of whether we should adapt multiple myeloma (MM) treatment to the measurable residual disease (MRD) status of the patient. Prof. Jackson describes the difference between the US and Europe and highlights how there are no studies that validate stopping therapy according to MRD negativity. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
